Foley Hoag’s highly trained, respected, and experienced patent prosecution professionals can meet your legal needs at many levels. We believe that strategic counsel for developing and managing intellectual property is essential to your ability to succeed in an increasingly sophisticated and competitive marketplace. And our clients’ success is our ultimate goal.
-
Federal Circuit Court Affirms ITC Ruling on Behalf of Global Bio-Chem Technology
[Read More]
-
Best Lawyers in America Names 27 Foley Hoag Lawyers to 2010 Guide
[Read More]
Publications more
- Biotech Patent Held Invalid For Failing to Disclose Preferred Host Cells [Read More]
- Commercializing Stem Cell-Based Therapies: Meeting NIH and FDA Requirements [Read More]
- EEC Perspectives - May 2009 [Read More]
- Trade Secrets: A Guidebook for Technical and Business Professionals Involved in Legally Protecting Products, Technologies and Services [Read More]
- Opportunities for the Life Sciences Industry: American Recovery and Reinvestment Act to Deliver $150 Billion for Healthcare [Read More]
Client Successes more
-
Global Bio-Chem Technology Group Company Limited
Our lawyers, in conjunction with Adduci, Mastriani & Schaumberg LLP and East Associates, represented Global Bio-Chem Technology Group Company Limited and its affiliates (GBT), the largest lysine producer in China and the largest vertically integrated corn-based biochemical manufacturer in Asia, which prevailed after an evidentiary hearing before the United States International Trade Commission (USITC) in a patent infringement investigation brought by Ajinomoto Heartland LLC and Ajinomoto Co., Inc. (Ajinomoto). In a ruling in July 2008, the Administrative Law Judge (ALJ) held that the claims of Ajinomoto’s two patents were invalid for failure to disclose the best mode of practicing the invention, thus finding no violation of Section 337 of the Tariff Act of 1930. The ALJ also ruled that both patents were unenforceable because Ajinomoto had committed inequitable conduct. [Read More]
-
Driving Biopharma Forward
Our lawyers identified, on the eve of FDA approval of one of our client's biopharmaceuticals, a prior public use that would cause a court to invalidate the otherwise blocking patent claims. This enabled our client to negotiate a license under the patent on commercially reasonable terms. [Read More]